<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940807</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/17/0448</org_study_id>
    <nct_id>NCT03940807</nct_id>
  </id_info>
  <brief_title>Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI in Adenomyosis</brief_title>
  <acronym>ADENOFIV</acronym>
  <official_title>Phase III Trial to Assess Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI Outcomes in Infertile Women Presenting With Adenomyosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adenomyosis is a benign condition defined as the invasion of ectopic endometrium into the
      myometrium, resulting in smooth muscle hyperplasia and endometrial inflammation, commonly
      associated with endometriosis and uterine fibroids.

      Heterogeneity among studies regarding diagnostic criteria and therapeutic management has fed
      the debate surrounding the impact of adenomyosis on assisted reproductive therapy outcomes.
      Nevertheless, recent data support that adenomyosis impairs reproductive outcomes associated
      with in vitro fertilization (IVF). According to several experimental data, prolonged exposure
      to gonadotropin releasing hormone (GnRH) agonists may overcome part of the detrimental impact
      of adenomyosis on fertility outcome. Overall, GnRH agonist treatment resulted in decreased
      local production of cytochrome P450 aromatase, decreased intrauterine concentration of free
      radicals and reduced inflammatory response and angiogenesis in endometrium, myometrium and
      adenomyosis lesions. At the same time, GnRH agonists affect neither endometrial capacity to
      support invasion nor invasive potential of the blastocyst in the early stages of
      implantation.

      For IVF, 2 main protocols based on GnRH agonist pituitary down-regulation are available:

        -  the long protocol involving a 15 days pituitary down-regulation;

        -  the ultra-long protocol involving a 3 months pituitary down-regulation. Most studies
           using ultra-long protocol reported similar IVF outcomes in adenomyosis patients and
           control groups. Conversely, studies involving long or GnRH antagonist protocols
           demonstrated a significant reduction in clinical and ongoing pregnancy rates in
           adenomyosis patients compared to control subjects. Thus supporting that ultra-long
           protocol may be beneficial to improve IVF outcomes in the setting of adenomyosis.This is
           what investigators would like to demonstrate in this study
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of live birth after first or second in vitro fertilization (IVF)/intra cytoplasmic sperm injection (ICSI) attempt.</measure>
    <time_frame>Up to 22 weeks of gestation</time_frame>
    <description>This outcome is defined as delivery of one or more live-born infant at &gt; 22 weeks of gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine volume change</measure>
    <time_frame>after 90 days desensitization in ultra-long protocol group and after 15 days desensitization in long protocol group</time_frame>
    <description>Uterine volume reduction between ultrasound measurements at baseline and at time of ovarian stimulation onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of poor responders</measure>
    <time_frame>after 90 days desensitization in ultra-long protocol group and after 15 days desensitization in long protocol group</time_frame>
    <description>Occurrence of poor responders defined as women with &lt;3 matures follicles or serum estradiol &lt;500 at the time of ovulation triggering</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum Human Chorionic Gonadotropin (HCG or ßhCG) ≥ 100 IU/l</measure>
    <time_frame>14 days following follicular aspiration</time_frame>
    <description>Biochemical pregnancy defined as serum Human Chorionic Gonadotropin (HCG or ßhCG) ≥ 100 IU/l, 14 days following follicular aspiration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>5 weeks after follicular aspiration</time_frame>
    <description>Implantation rate defined as the ratio &quot;number of gestational sacs/number of transferred embryos&quot; on TV US performed 5 weeks after follicular aspiration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with clinical pregnancy</measure>
    <time_frame>5 weeks after follicular aspiration</time_frame>
    <description>Clinical pregnancy defined as the presence of one or more gestational sacs on transvaginal ultrasound performed 5 weeks after follicular aspiration, including ectopic pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with clinical pregnancy with fetal heart beat</measure>
    <time_frame>7 weeks after embryo transfer</time_frame>
    <description>Clinical pregnancy with fetal heart beat defined as the presence of at least one fetus with heart beat on transvaginal ultrasound performed 7 weeks after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with ongoing pregnancy</measure>
    <time_frame>12 weeks of gestation</time_frame>
    <description>Ongoing pregnancy defined as a live pregnancy on first trimester US examination performed at 12 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First trimester miscarriage occurrence</measure>
    <time_frame>Before 12 weeks of gestation</time_frame>
    <description>First trimester miscarriage occurrence defined as a pregnancy loss before 12 weeks of gestation among patients with a clinical pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of menopause-like symptoms symptoms at the end of the GnRH agonist treatment</measure>
    <time_frame>after 90 days desensitization in ultra-long protocol group and after 15 days desensitization in long protocol group</time_frame>
    <description>Using the Menopause Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of neonatal complications</measure>
    <time_frame>Until 6 weeks post-partum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any other Adverse Event</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of pregnancy and post-partum complications</measure>
    <time_frame>Until 6 weeks post-partum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">674</enrollment>
  <condition>Adenomyosis</condition>
  <arm_group>
    <arm_group_label>Ultra-long protocol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All women will receive one intra-muscular administration of 11.25 mg Gonadotropin Releasing Hormone (GnRH) agonist (triptorelin acetate) on luteal phase of their menstrual cycle. Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period. Ovarian stimulation will be started after 90 days desensitization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long protocol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous application of 0.1mg of GnRH agonist (triptorelin acetate) started on luteal phase of their menstrual cycle. Ovarian stimulation will begin after 15 days desensitization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11.25mg GnRH agonist</intervention_name>
    <description>Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.
After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support.</description>
    <arm_group_label>Ultra-long protocol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1 mg GnRH agonist</intervention_name>
    <description>Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.
Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support.</description>
    <arm_group_label>Long protocol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 µg transdermal oestradiol</intervention_name>
    <description>Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.</description>
    <arm_group_label>Ultra-long protocol group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. suspected adenomyosis on high quality transvaginal ultrasound or focal or diffuse
             adenomyosis defined as a thickening of the junctional zone to more than 12mm on
             previous magnetic resonance Imaging (&lt;6 months)

          2. infertility of any cause requiring IVF or ICSI

          3. infertility period of at least 1 year except for women with history of deep
             infiltrating endometriosis or bilateral salpingectomy

          4. age &gt;18 and &lt; 40 years

          5. complete fertility workup comprising for women hormone serum measurement
             (anti-mullerian hormone (AMH), estradiol, follicle stimulating hormone (FSH),
             luteinizing hormone (LH)), high quality transvaginal ultrasound and, when applicable,
             hysterosalpingography, diagnostic laparoscopy or hysteroscopy

          6. first or second IVF or ICSI attempt

          7. absence of severe premature ovarian insufficiency defined by antral follicle count &lt; 8
             and AMH &lt; 1ng/ml

          8. meet the criteria from the French law to be included in an assisted reproductive
             technique program

          9. informed written consent for both women and men

         10. social security cover for both women and men

        Exclusion Criteria:

          1. absence of adenomyosis (defined as a thickening of the junctional zone to more than
             12mm) on pelvic MRI

          2. other potential causes of implantation failure: leiomyoma, endometrial polyp, not
             removed hydrosalpinx, malformed uterus (unicornis, bicornis, septate, duplex),
             antiphospholipid syndrome

          3. medical contraindication to study treatments (GnRH agonist and add-back therapy)

          4. women taking prohibited concomitant treatments and not able to stop them for the study
             period

          5. medical contraindication to assisted reproductive technique and/or pregnancy
             including: uncontrolled type I and II diabetes; undiagnosed liver disease or
             dysfunction; renal insufficiency; history of deep venous thrombosis, pulmonary
             embolism or cerebrovascular accident; uncontrolled hypertension; known symptomatic
             heart disease; history of or suspected cervical carcinoma, endometrial carcinoma,
             ovarian carcinoma or breast carcinoma; undiagnosed vaginal bleeding; genetic
             abnormalities

          6. positive plasma viral load for human immunodeficiency virus(HIV), hepatitis C virus
             (HCV) or hepatitis B virus (HBV) for one (or both) in the couple during the year
             before inclusion

          7. participation in another research study including an exclusion period which has not
             expired at the time of screening

          8. patients subject to a judicial safeguard order, guardianship or trusteeship.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien Vidal</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabien Vidal, MD</last_name>
    <phone>05 67 77 13 70</phone>
    <email>vidal.fabien@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celia Bettiol, CRA</last_name>
    <phone>05 67 77 13 87</phone>
    <email>bettiol.c@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-Emmanuel Bouet, MD</last_name>
      <email>pierreemmanuel.bpuet@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Emmanuel Bouet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Aliénor d'Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Claude Hocke</last_name>
      <email>claude.hocke@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Claude Hocke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Merviel</last_name>
      <email>philippe.merviel@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Merviel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nathalie Massin, MD</last_name>
      <email>Nathalie.Massin@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie Massin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble-Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laure Villaret, MD</last_name>
    </contact>
    <contact_backup>
      <email>LVillaret@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laure Villaret, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise-Marie Durand, MD</last_name>
      <email>Lise-Marie.Durand@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Lise-Marie Durand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Conception Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Blandine Courbière, MD</last_name>
      <email>blandine.courbiere@univ-amu.fr</email>
    </contact>
    <investigator>
      <last_name>Blandine Courbière, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>André Bongain</last_name>
      <email>bongain.a@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>André Bongain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphanie Huberlant</last_name>
      <email>Stephanie.HUBERLANT@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie Huberlant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Poissy</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Khadija Fathallah, MD</last_name>
      <email>kfathallah@chi-poissy-st-germain.fr</email>
    </contact>
    <investigator>
      <last_name>Khadija Fathallah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen Normandie</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Letailleur, MD</last_name>
      <email>maria.letailleur@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Maria Letailleur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier des 4 villes</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Joelle Belaisch-Allart</last_name>
      <email>j.belaischallart@ch4v.fr</email>
    </contact>
    <investigator>
      <last_name>Joelle Belaisch-Allart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine Rongieres</last_name>
      <email>catherine.rongieres@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Rongieres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabien Vidal, MD</last_name>
      <email>vidal.fabien@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Fabien Vidal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>GnRH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

